Why I’d STILL Buy AstraZeneca plc Despite Its 10% Share Price Jump

Royston Wild explains why pharma giant AstraZeneca plc (LSE: AZN) remains a hot pick despite recent gains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in medicines play AstraZeneca (LSE: AZN) have endured a tumultuous ride during the past month amid swirling investor appetite.

The London firm saw its value collapse by a tenth in just over a fortnight at one point in August, pushing AstraZeneca to levels not visited since April 2014 around £39 per share. But shares have rocketed back up since then and the business was recently dealing around £42.80 per share, up 10% from last month’s troughs.

I wouldn’t rule out further volatility, naturally, as the prospect of more worrying economic data from China is a strong possibility. Still, for more patient investors I believe AstraZeneca is a terrific stock selection as a rejuvenated product pipeline looks set to deliver brilliant long-term gains.

Emerging markets remain strong

AstraZeneca’s weakness last month in light of rising fears over China, and therefore growth markets across South-East Asia and beyond, is understandable given the firm’s growing reliance on these geographies. The business saw emerging market sales rocket 14% higher during January-June, and sales to Chinese health providers leapt 19% in the period to $1.3bn.

AstraZeneca has logically put developing regions near the top of its growth strategy, and is “accelerating investment in… emerging markets’ capabilities, with a focus on China and other leading markets such as Russia and Brazil.

 Indeed, global healthcare spend should continue to climb in the years ahead as economic growth in new regions steams higher and the needs of a rising middle class increase. And AstraZeneca is putting itself at the front of the queue by upping its expenditure in these territories.

Great value across the board

Despite AstraZeneca’s recent charge back up the share price charts, I believe the business still provides plenty of bang for one’s buck. The impact of further exclusivity losses are expected to cause a marginal earnings slip in 2015 — a fourth successive decline if realised — and an extra 4% drop is chalked in for 2016.

However, these projections still produce very-attractive P/E multiples of 15.3 times and 15.9 times correspondingly — any reading around 15 times is broadly considered decent value. On top of this, AstraZeneca is expected to keep the full-year dividend locked at 280 US cents per share in both 2015 and 2016, yielding a FTSE-bashing 4.2%.

The business of drugs development is fraught with perils, of course, where disappointing clinical results can result in expensive product launch delays, not to mention many products failing to even leave the lab bench.

But with AstraZeneca doubling-down on developing the next generation of earnings drivers — core R&D investment advanced 24% in January-June, to $2.64bn — expanding its lab network across the globe, and building its position exciting growth areas like diabetes and respiratory care, I believe the firm’s growth prospects for the years ahead are compelling.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »